Form D · Biotechnology

FOXKISER Ventures IV, LLC

Washington, DC · CIK 0001700147

Offering snapshot reported Feb 28, 2018 · SEC filing

Reported sold
$1.03M
Offering amount: $1.03M
Investors reported
11
Form D · investor count
Minimum accepted
$25.6K
Reported outside-investor minimum
First sale
Feb 28, 2017
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$513K$1.03MMar 8, 2017: $1,025,000.00Mar 8, 2017Feb 28, 2018: $1,025,000.00Feb 28, 2018

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 28, 2018Amendment$1,025,000$0vs Mar 8, 201711SEC filing
Mar 8, 2017Initial$1,025,000No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-282037

Source: Form D, filed Feb 28, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Allan M. Fox Executive
John Daniel Kiser Executive
Daniel O'donnell Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1701 Pennsylvania Avenue Nw Suite 900
Washington, DC, 20006